Table S3. Supplementary data of the ROC curves in different groups in both test and validation cohorts.

Group	Test				Validation
	Prevalence	z statistic	P value		Prevalence	z statistic	P value
VI vs. NVI (in total)
PON1	41.2	11.373	<0.0001		45.8	17.013	<0.0001
AFP		6.730	<0.0001			2.124	0.0336
PON1 + AFP		13.570	<0.0001			17.938	<0.0001
MVI vs. NVI (in total)
PON1	36.9	9.757	<0.0001		38.4	14.264	<0.0001
AFP		5.103	<0.0001			1.383	0.1668
PON1 + AFP		11.380	<0.0001			15.103	<0.0001
VI vs. NVI (in sHCC sub-group)
PON1	31.1	8.043	<0.0001		35.6	16.446	<0.0001
AFP		2.271	0.0231			1.617	0.1058
PON1 + AFP		8.222	<0.0001			17.531	<0.0001
MVI vs. NVI (in sHCC sub-group)
PON1	29.0	7.272	<0.0001		31.3	15.024	<0.0001
AFP		1.418	0.1561			1.424	0.1544
PON1 + AFP		7.286	<0.0001			16.418	<0.0001
VI vs. NVI (in advanced HCC sub-group)
PON1	60.3	7.738	<0.0001		64.0	5.601	<0.0001
AFP		5.983	<0.0001			0.343	0.7317
PON1 + AFP		9.687	<0.0001			6.745	<0.0001
MVI vs. NVI (in advanced HCC sub-group)
PON1	54.0	6.491	<0.0001		53.6	4.338	<0.0001
AFP		5.178	<0.0001			0.262	0.7930
PON1 + AFP		8.172	<0.0001			5.263	<0.0001

VI, vascular invasion; NVI, no vascular invasion; MVI, micro-vascular invasion; AFP, α-fetoprotein; PON1, paraoxonase 1.